## Note
nid: 1514570771562
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::!FLAG_THESE_CARDS::!DELETE, #AK_Step1_v11::#FirstAid::03_Microbiology::07_Antimicrobials::26_Antimycobacterial_Therapy, #AK_Step1_v11::#FirstAid::03_Microbiology::07_Antimicrobials::28_Isoniazid, #AK_Step1_v11::#OME_banner::Basic_Science::08_Microbiology::20_Antimycobacterials, #AK_Step1_v11::#SketchyPharm::07_Antimicrobials::03_Antimycobacterials::01_Tuberculosis_Drugs::zanki_extra, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^FA_Updates::FA2018, #AK_Step1_v11::^Other::^HighYield::3-HighYield-temporary
markdown: false

### Text
People who have <u>decreased</u> levels of the liver enzyme
{{c1::<b>n-acetyltransferase 2 (NAT2)</b>}} lead to an increased
risk** of <u>toxicity</u>

### Extra
- NAT2 is the main metabolic enzyme for INH
<div>
  <div>
    - People who have decreased levels of NAT2 are deemed "slow"
    acetylators, and those who have normal are deemed "fast"
    acetylators
  </div>
  <div>
    <img src="paste-255133942284289.jpg">z
    <div>
      - **Recent literature has shown this to have an pathologic
      effect (as seen via research articles and reviews from 2017
      to 2016), but this is still controversial (Boards and Beyond)
    </div>
  </div>
</div>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid
<img src="paste-457907938263043.jpg"><img src=
"paste-461352502034435.jpg"><img src="paste-463057604050947.jpg">
<div><img src="paste-174826643783683.jpg"></div>

### Sketchy
<img src="paste-235686330368001.jpg"> <img src=
"paste-66c7354fc8106dbad422fb1cb1261f23fc1634e3.png">

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href=
  "https://onlinemeded.org/spa/microbiology/antimycobacterials/acquire?ref=anki">
  <img src="_OME_AnkiFlashcards_Lesson_2.png"></a>
</div>

### Additional Resources


### One by one

